593 results about "Target drug" patented technology

The invention discloses a colorectal cancer drug relocation method based on multi-omics integration. The system comprises a multi-omics data acquisition and preprocessing module, a tumor microenvironment analysis module, a specific disease network construction module, a multi-dimensional drug relocation module and a result evaluation module. And the tumor microenvironment analysis module comprises cell heterogeneity identification, cell map construction, cell annotation and tumor cell subset annotation. The specific disease network construction module comprises tumor feature expression program extraction, expression program screening, meta-program construction, clinical related meta-program recognition and specific disease protein interaction network construction. And the multi-dimensional drug relocation module comprises a module for identifying diseases by using a random walk algorithm, carrying out drug screening based on disturbance data, carrying out drug screening based on network proximity and carrying out comprehensive drug relocation. From the perspective of single cell data, element programs related to colorectal cancer survival are excavated, corresponding modules are designed, and the efficiency and precision of colorectal cancer targeted drug screening are improved.

The present application relates to a kind of dihydrocarbylimidazole biomimetic lipid compound and its preparation method and application, dihydrocarbylimidazole biomimetic lipid compound structure imitates natural phospholipid design, modification is not less than 10 carbon atoms alkyl on the 4th and 5th of imidazole, and modification is different alkyl chain length primary amine on 2nd position;Dihydrocarbylimidazole biomimetic lipid compound is mixed with therapeutic drug and other adjuvant, can be prepared to be loaded in the lipid nanoparticle of therapeutic drug, can be used as drug delivery system for the preparation of brain-targeted drug.Dihydrocarbylimidazole biomimetic lipid has the function of dynamic control blood-brain barrier, can realize the reversible opening of blood-brain barrier;Formed drug-loaded lipid composition can cross blood-brain barrier and better realize the brain-targeted delivery of loaded therapeutic drug;Drug-loaded lipid composition consisting of dihydrocarbylimidazole biomimetic lipid belongs to a new generation of biomimetic nanomedicine carrier, provides new strategy for realizing the brain-targeted delivery of different kinds of drugs.

The invention discloses a tumor cholesterol metabolism regulation microneedle patch and a preparation method, the microneedle patch comprises a needle tip and a backing which are connected, the needle tip comprises a needle tip body and nanoparticles loaded on the needle tip body, the nanoparticle is a manganese ion-doped organic metal framework, the outer layer of the manganese ion-doped organic metal framework is modified with a targeting agent, cholesterol oxidase and superoxide dismutase are carried on the manganese ion-doped organic metal framework, the targeting agent can target a CD44 receptor, and the organic metal framework can carry drugs. The targeted drug can enter tumor cells in a targeted mode, superoxide dismutase catalyzes superoxide anions overexpressed in the tumor cells to generate H2O2 and O2, O2 needed by catalysis is provided for cholesterol oxidase, cholesterol at the tumor site is consumed by the cholesterol oxidase, accumulation of 7-DHC is reduced, meanwhile H2O2 can be generated, and the cholesterol oxidase can be used for catalyzing the tumor site. H2O2 is catalyzed by manganese ions through a Fenton-like reaction to generate OH to induce tumor cells to generate ferroptosis, so that ferroptosis-immune synergistic treatment is realized.

According to the GPX4 protein degradation agent and the application, the degradation agent serves as molecular glue to induce tumor cell ferroptosis and is different from an existing PROTAC technology, and the molecular glue can induce interaction between E3 ubiquitin ligase and target protein GPX4 and promote ubiquitination of the E3 ubiquitin ligase and the target protein GPX4. Compared with the existing GPX4 degradation agent, the molecular glue has the advantages of small molecular weight, high cell permeability and better druggability. The GPX4 molecular glue disclosed by the invention can be used for effectively degrading GPX4 and has a killing effect on various tumor cell lines. The preparation method is simple in synthesis route and mild in reaction condition, can be used for being developed into a new generation of GPX4 targeting drugs, and has great clinical application value and considerable market potential.

The invention relates to the technical field of information processing, in particular to a medicine conflict automatic detection and prescription optimization system for old multi-disease patients. According to the system, a data management module is used for collecting individual data of patients and group data of co-diseased reference groups and receiving a planned medication scheme; the parameter calculation module is used for identifying a target medicine combination with time overlapping in the patient medication record and the planned medication scheme; determining a basic risk index according to the group medication response data, the patient medication record and the work and rest text data; determining a lag risk coefficient according to the physiological indexes and the drug metabolism data; determining group medication associated risk parameters according to atypical reactions and group medication records in the medication reaction data; the risk fusion module is used for determining a drug use conflict risk value based on the basic risk index, the lagging risk coefficient and the group drug use associated risk parameter; and the prescription optimization module is used for generating an optimal medication scheme, so that the generated optimal scheme is more suitable for the actual life of the patient.

The invention discloses a data management system and method based on a large model, and relates to the technical field of big data analysis, and the method comprises the steps: setting a data monitoring management period, enabling the system to collect the stock change information of various types of medicines in a hospital, analyzing the historical warehouse-out data of a department in combination with a time sequence model, and precisely measuring and calculating a first warehouse-out predicted value; and comparing the daily average dose with a standard limited daily dose, deeply mining compatible drug data associated data in an auxiliary drug use scene, analyzing a compatible drug data ex-warehouse trend, and accurately mastering a collaborative consumption rule. By tracking ex-warehouse proportion changes of target drug data and compatible drug data in a historical period, predicting a proportion trend, predicting ex-warehouse quantity in combination with the compatible drug data, dynamically calculating an auxiliary drug use demand, and deeply deconstructing inventory change data, prospective pre-judgment of the inventory change data is realized, hospitals are assisted to optimize an inventory structure, and the workload of the hospitals is reduced. And the accuracy and response efficiency of inventory data management are improved.

Theranostic targeted ultrasonic blasting nano-bubbles, a preparation method therefor, and use thereof, wherein the nano-bubbles are the targeted drug-gene nano-bubbles miRNA / FTY720 / PFP@PEI-T7 NBs. The nano-bubbles can be used for preparing a thyroid ultrasound diagnostic agent or a drug for treating thyroid cancer.

The invention relates to the technical field of image analysis, in particular to a targeted drug curative effect prediction method based on image recognition, which comprises the following steps: acquiring tissue images and nuclear morphological parameters by a microscope, establishing a database in combination with transcripts, extracting an injury area, recognizing image features through a convolutional neural network, and constructing a prediction model; and inputting candidate drug molecular structures for molecular docking, calculating a repair progress by combining animal verification to establish a curative effect model, predicting drug scores and response time based on the curative effect model to generate a ranking list, screening high-score drug cells, verifying monitored survival, comparing, predicting and outputting a result. The method comprises the following steps: extracting a cell nucleus form, revealing a relation between damage and molecular abnormality in combination with a transcriptome, identifying a target spot corresponding to an abnormal mode and pathological change through deep learning, performing affinity prediction and animal verification on a drug structure, quantifying the repair progress by adopting image difference, and evaluating the curative effect with two dimensions of structure and function. And curative effect scores and response prediction are output to realize system sequencing, so that drug screening is more accurate and practical.

The invention discloses a drug relocation method and system based on heterogeneous knowledge and structure fusion, and belongs to the technical field of medical care informatics. The method comprises the following steps: constructing a biomedical domain knowledge heterogeneous graph; generating disease knowledge embedding and drug knowledge embedding corresponding to a target drug-disease pair based on the biomedical domain knowledge heterogeneous graph; generating disease structure embedding and drug structure embedding corresponding to the target drug-disease pair by constructing a drug-drug similarity network, a disease-disease similarity network and a drug-disease association network; and based on disease knowledge embedding, drug knowledge embedding, disease structure embedding and drug structure embedding, obtaining a drug relocation result. According to the method, complex biological network characteristics are accurately captured and complex entity information is finely modeled through an innovative drug relocation model, so that accurate drug relocation is realized.

The invention discloses a multi-target drug molecule generation model construction method and a multi-target drug design method, and relates to computer drug design and bioinformatics. Determining a corresponding two-dimensional molecular map based on the SMILES sequence; the fully-connected pharmacophore diagram and the two-dimensional molecular diagram are used as input of a GatedGCN module, each atomic node in the two-dimensional molecular diagram is connected with all pharmacophore nodes in the fully-connected pharmacophore diagram in message transmission, and information exchange between different nodes is achieved; the masked SMILES sequence serves as the input of an encoder, and the decoder generates an SMILES sequence conforming to pharmacophore characteristics in an autoregression mode; freezing the network parameters of the GatedGCN module and the encoder; and training the multi-target drug molecule generation model through the elite multi-target molecule set, and reversely optimizing and updating decoder network parameters according to an output result. According to the method, the model fully learns the multi-target molecular structure characteristics, and the multi-target drug molecule generation accuracy is improved.

The invention belongs to the technical field of biological medicines, and discloses application of vitamin K3 in preparation of a medicine for treating psoriasis. The invention finds that the compound vitamin K3 can obviously inhibit the activation of the STING downstream immune pathway and has an inhibition effect on the activation of the STING pathway. A mouse psoriasis model is formulated according to the absorption and metabolism characteristics of the inhibitor VK3, and it is proved that the VK3 can significantly inhibit the process of psoriasis and up-regulation of an STING pathway at an affected part in a transdermal drug delivery mode. The STING pathway does not belong to a main pathway affecting the course of disease in most non-immunodeficient inflammatory diseases, so that a better treatment effect may be generated by using the STING pathway in combination with a direct treatment drug (such as an IL-17A antibody for psoriasis). The vitamin K3 is simple in chemical structure, mature in production process and low in preparation cost, has more remarkable price advantage compared with biological agents and small-molecule targeting drugs, and has high popularization value and application prospects.

The invention relates to the technical field of extracellular vesicles, in particular to an extracellular vesicle active drug loading method which comprises the following preparation steps: S1, collecting cell supernatant, collecting the cell supernatant under the condition of 4 DEG C, and performing multi-stage centrifugation to remove impurities to obtain purified extracellular vesicles; s2, dissolving a target drug in a corresponding solvent to prepare a drug solution with the concentration of 0.1-5 mg / mL; s3, mixing the purified extracellular vesicles obtained in S1 with the medicine solution obtained in S2 according to the volume ratio of 1: 1, and performing low-frequency ultrasonic treatment in a pulse mode under the ice bath condition of 4 DEG C; s4, incubating the mixed system subjected to ultrasonic treatment at 37 DEG C for 25-35 minutes, and meanwhile, adding a cholesterol solution with the final concentration of 0.005-0.01% to assist membrane repair; the problems of contradiction between the drug loading efficiency and the integrity of the extracellular vesicles, poor drug universality, low purification efficiency and insufficient application stability in the existing active drug loading technology of the extracellular vesicles are specifically solved through the whole process optimization of precise purification, efficient drug loading, directional repair and deep refining.

The invention belongs to the technical field of pesticides, and particularly relates to azobenzene calix [4] arene derivatives as well as a preparation method and application thereof. The invention discloses a novel azobenzene calix [4] arene derivative prepared by directional modification through an azo reduction reaction based on a calix [4] arene skeleton. The azobenzene calix [4] arene derivative has the characteristics of green environmental protection, accurate and controllable structure and efficient synthesis. After the derivative and a pesticide form a host-guest compound, the activity of the pesticide can be remarkably improved, the bioavailability of the pesticide at an action site is increased, the problem of low efficiency of the traditional pesticide is effectively solved, and the development of target drug resistance is delayed. The technology breaks through the technical bottleneck of nano-carrier environmental toxicity, provides a new thought for developing a multi-target and low-environmental-risk pesticide synergist, and has important significance for realizing pesticide decrement, synergism and resistance treatment.

The present application relates to the technical field of targeted cargo delivery, and more particularly to a drug loading and delivery method and a cell carrying method of core-shell mesoporous micro-nanorobot. The drug loading and delivery method is realized based on the drug loading capacity of the mesoporous structure, the magnetism of the iron oxide core and the photothermal effect of the polydopamine shell. The core-shell mesoporous micro-nanorobot can adsorb and load drugs through the capillary force and electrostatic force generated by the mesoporous structure; then the movement of the core-shell mesoporous micro-nanorobot is driven by an external magnetic field; when the core-shell mesoporous micro-nanorobot approaches the target area, the pore structure is irradiated by near-infrared light, the temperature of the pore structure is increased and the thermal vibration is accompanied, the drugs in the mesoporous structure are effectively released to the target area, and the drug delivery effect is achieved. At the same time of drug loading and delivery, the core-shell mesoporous micro-nanorobot has a carrying capacity after clustering under the magnetic field, and carries cells through two methods of eddy current carrying and contact adhesion. The targeted cargo delivery of targeted drugs and cells and other cargos can be realized by the micro-nanorobot.

The invention relates to an antibody drug conjugate as well as a preparation method and application thereof, the preparation method of the antibody drug conjugate comprises the following steps: S10, obtaining a wild type antibody, and carrying out hydrolysis reaction on galactose at the tail end of a sugar chain of the wild type antibody to obtain an antibody of which the tail end is four GlcNAc sugar types; s20, obtaining B4GALT1 (Y286L), mixing the UDP-GalNAz, the B4GALT1 (Y286L) and the antibody, and carrying out an enzymatic reaction so as to transfer the azido galactose to the tail end of a carbohydrate chain of the antibody, so as to obtain a carbohydrate chain modified antibody; and S30, mixing a target drug with the carbohydrate chain modified antibody, and carrying out a one-step click chemical reaction to obtain the antibody drug conjugate. The galactose hydrolase can retain four GlcNAc sites, and after the galactose hydrolase is connected with GalNAz, four target drug molecules can be combined, the DAR value of the antibody drug conjugate is increased, and the drug activity of the antibody drug conjugate is improved.

The invention discloses a shoulder operation rapid rehabilitation regulation and control system combined with an analgesia path, and the system firstly collects signals in real time through a multi-mode physiological sensing network, constructs a shoulder dynamic function spectrogram reflecting pain and functional states, and recognizes a functional abnormality core region; then, a targeted drug infusion system is controlled, and a personalized analgesia path matched with the physiological response of the object is generated in combination with a multi-physics field coupling model and a model prediction control algorithm; thirdly, calculating the comprehensive rehabilitation confidence coefficient for quantifying the rehabilitation potential by analyzing the space-time correlation between the functional spectrogram and the analgesia path; and finally, based on the comprehensive rehabilitation confidence, generating a safe, effective and object-tolerant personalized rehabilitation training instruction set by using a multi-target rehabilitation optimization model, and driving rehabilitation equipment to execute. The method has the following advantages and effects: precise space-time matching and dynamic coordination of analgesia and rehabilitation training are realized, so that the rehabilitation efficiency and quality are remarkably improved on the premise of ensuring safety.

The invention discloses a myocardial ischemia reperfusion injury animal model construction method and application thereof in the technical field of model animal preparation. The method comprises the steps of hypertension and hyperlipidemia pretreatment, standardized ischemia-reperfusion operation, immune microenvironment regulation and control and model evaluation and verification. According to the invention, model construction is carried out on an integrated model operation table, so that a standardized ischemia-reperfusion process is realized, reproducibility of a myocardial injury degree and an immune cell infiltration rule of the model is realized, and suitability of the model and nano-drug research is enhanced; and a reliable tool is provided for research and development of targeted drugs such as immune cell membrane coated nanoparticles.

The embodiment of the invention provides a drug optimization method and system based on the overall effect of a protein network. The method comprises the following steps: constructing a protein interaction network related to a target disease, and dividing each protein target into a risk protein set and a protection protein set; respectively calculating first binding affinity data of the candidate drugs and each protein target in the risk protein set, and generating a first network comprehensive score based on the first binding affinity data; respectively calculating second binding affinity data of the candidate drugs and each protein target in the protection protein set, and generating a second network comprehensive score based on the second binding affinity data; calculating network confrontation scores of the candidate drugs according to the first network comprehensive score and the second network comprehensive score; and determining whether the candidate drug is a preferred drug based on the network adversarial score. The method can overcome the defect that a single-target drug is insufficient in curative effect due to a network compensation effect, so that safer and more effective candidate drugs are screened out.

The invention relates to application of an SLC30A9 inhibitor in preparation of an anti-tumor medicine, and belongs to the technical field of biological medicines. The invention provides an application of an SLC30A9 inhibitor in preparation of an anti-tumor drug. The expression of SLC30A9 is down-regulated to activate a cGAS-STING-NF-kappa B pathway, so that apoptosis of osteosarcoma cells is promoted, killing of the osteosarcoma cells by MTX is enhanced, and sensitivity of the osteosarcoma cells to MTX chemotherapy is recovered. Through combined application of SLC30A9 knock-down, a cGAS-STNG-NF-kappa B pathway agonist and MTX for chemotherapy, the killing effect of MTX on osteosarcoma cells can be remarkably enhanced, tumor cell proliferation is inhibited, and the treatment effect is improved. The core effect of the SLC30A9 in an osteosarcoma chemotherapy drug resistance mechanism is defined, and a theoretical basis and a technical support are provided for subsequent development of targeted drugs aiming at a cGAS-STNG-NF-kappa B pathway.

The invention discloses a method for establishing a hemophagocytic syndrome in-vitro cell disease model, and belongs to the technical field of biology. Based on human PBMC construction, the reaction of a human immune system can be truly reflected, experimental result deviation caused by species difference in an animal model is avoided, and a more accurate model basis is provided for research of human diseases. In addition to T cell over-activation, the HLH model of the present application has a clear key feature of NK cell reduction, which is HLH, accompanied by up-regulation of cytokines such as interferon-gamma and IL-10. The establishment process of the model is rapid and efficient, the experimental period is remarkably shortened, a large number of samples or drugs can be rapidly screened, the research efficiency is improved, and the conversion process from basic research to clinical application is accelerated. The method can be used for researching various mechanisms related to the HLH, is beneficial to more comprehensive understanding of pathogenesis of the HLH, and provides a theoretical basis for developing preliminary screening of targeted drugs.

The invention provides a medical information processing method and device and electronic equipment, and can be applied to the technical field of medical supply chains. The method comprises the following steps: identifying a target area image on a target drug package to obtain a target drug traceability code; performing identification analysis on the target drug traceability code to obtain a target drug identification code; on the basis of the target drug identification code, querying from a drug information database to obtain target drug information associated with the target drug traceability code; the target drug traceability code, the target drug information and the user medical insurance account information are respectively filled in an order page and are displayed; and in response to completion of the transaction based on the order page, associating the target drug traceability code with the user medical insurance account information.

The invention discloses a photosensitizer, dynamic antibacterial hydrogel containing lipidosome wrapping the photosensitizer and a preparation method and application of the dynamic antibacterial hydrogel, and belongs to the technical field of biological materials. The invention provides a novel D-A-D type photosensitizer TPT which is simple in structure and simple in synthetic route, and from the angles of safety, practicability and use specificity of hydrogel dressing, modified hyaluronic acid and modified carboxymethyl chitosan are used as raw materials, cationic liposome wrapping the novel photosensitizer TPT is carried, and the hydrogel dressing is prepared. The efficient antibacterial dynamic cross-linked hydrogel material is prepared. The hydrogel disclosed by the invention has two pH response bonds, namely an imine bond and a boric acid ester bond, and has good moisture retention and biocompatibility; meanwhile, the hydrogel is loaded with the cationic liposome wrapping the novel photosensitizer TPT, so that the hydrogel has excellent active oxygen yield. The hydrogel disclosed by the invention aims to quickly resist bacteria, promote wound healing, reduce infection risk and improve the success rate of treatment through the targeted drug release function of the intelligent hydrogel.

The present application relates to a drug or pharmaceutical composition for preventing, alleviating, or treating cancer and a use thereof, as well as a method for preventing, alleviating, or treating cancer. The drug or pharmaceutical composition of the present application is capable of interfering with ataxia-telangiectasia mutated and Rad3-related kinase (ATR) and mammalian target of rapamycin (mTOR) activity, causing inactivation or reduced activity of ATR and mTOR. The present application provides a novel dual-target strategy for the treatment of cancer.

The invention relates to an anti-CD7 nano antibody and application thereof, the antibody comprises a heavy chain variable region, and the heavy chain variable region comprises CDR1, CDR2 and CDR3. According to the invention, the anti-CD7 antibody is screened, and the anti-CD7 antibody only comprises a heavy chain variable region, has high affinity and specificity, can efficiently target a CD7 antigen, is simple in structure and easy to prepare, and has important application value in the field of preparation of drugs taking CD7 as a target spot.

The invention belongs to the field of traditional Chinese medicines, and provides astragalus membranaceus and jujube heart-protecting granules as well as a preparation method and application thereof, and the astragalus membranaceus and jujube heart-protecting granules are prepared from the following medicinal materials: raw astragalus membranaceus, codonopsis pilosula, semen ziziphi spinosae, salvia miltiorrhiza, angelica sinensis, ligusticum wallichii and cassia twig. The astragalus membranaceus and jujube heart-protecting granules are convenient to carry and take, experiments prove that the astragalus membranaceus and jujube heart-protecting granules are helpful for preventing or treating cardiotoxicity of targeted drugs and / or immune examination inhibitors, and a new solution is provided for expanding the application of astragalus membranaceus and jujube heart-protecting prescriptions and solving the problem of cardiotoxicity of traditional Chinese medicines for tumor treatment.

The invention relates to a binding protein B capable of binding with klebsiella pneumoniae and application of the binding protein B, and belongs to the technical field of molecular biology and protein engineering. The binding protein B provided by the invention can be specifically bound with an extramembrane part of a specific protein P24017. OMPAKLEPN of klebsiella pneumoniae, and experiments such as bimolecular fluorescence complementation and flow cytometry prove that the binding protein B has good recognition and stable binding capacity on the klebsiella pneumoniae, can be used for identifying and screening the klebsiella pneumoniae, and has good application prospects. And a key tool is provided for targeted drug development aiming at the bacterium.

The invention discloses a rapid and accurate high-throughput drug screening system based on deep learning, and relates to the field, and the method comprises the steps: obtaining molecular structure data containing two-dimensional structural features and three-dimensional conformation features in a to-be-screened drug molecular library, and converting the molecular structure data into a numerical feature matrix; and constructing a feature association network based on the feature matrix, identifying influence nodes through node connectivity, and determining a dynamic weight coefficient. And performing weighted reconstruction on the feature matrix by using the dynamic weight coefficient to generate optimized feature data, and calculating the binding strength and spatial complementarity of the candidate drug molecules and the target sites to obtain molecular activity distribution data. Constructing a map according to the activity distribution data, determining an initial screening interval, and optimizing and adjusting the screening interval by calculating a structural skeleton difference value between candidate molecules, so as to screen out target drug molecules. According to the method, large-scale drug molecule screening work can be rapidly and accurately completed, and the drug research and development efficiency is improved.

The invention provides a screening method of a targeted drug for inhibiting accumulation of trimethylamine and / or trimethylamine-N-oxide. The screening method comprises the following steps: determining an action target on a metabolic pathway of trimethylamine and / or trimethylamine-N-oxide; if the target is protein, preliminarily screening candidate components based on the three-dimensional structure of the target; the candidate component is validated to confirm the targeted drug. According to the method, large-scale screening of targeted drugs aiming at targets can be achieved, the targeted drugs inhibit accumulation of trimethylamine and / or trimethylamine-N-oxide in the body by influencing the metabolic pathway of trimethylamine and / or trimethylamine-N-oxide, side effects are small, and the normal metabolic process of the human body is prevented from being influenced.

In accordance with at least one aspect of this disclosure, a method for preparing a patient for a diagnostic procedure and / or for receiving a therapy using a disease targeted drug is provided. The method can include the steps of a) identifying one or more soluble targets detectable in plasma of the patient; and b) extracorporeally removing the soluble targets from the plasma of the patient. Extracorporeally removing the soluble targets from the plasma of the patient can include using plasmapheresis or immunoadsorption to prepare a patient for a procedure using disease targeted treatment or diagnostics. Additionally, or alternatively, dose modulation can be used to proportionally increase the concertation of the diagnostic / treatment agent relative to the concentration of the soluble target in the blood, improving the outcome treatment and diagnostic procedures over conventional methods.

The invention discloses a method for screening a medicine for treating liver injury caused by polygonum multiflorum based on biochemical indexes and application of the method. The method comprises the following steps: constructing a polygonum multiflorum induced liver injury animal model; the target drug is applied to the fleece-flower root-induced liver injury animal model, the fleece-flower root-induced liver injury animal model is administered according to a fixed time period, and the leucoglobulin ratio, the total protein content and the globulin content in the blood plasma of the fleece-flower root-induced liver injury animal model are detected. The leucoglobulin ratio, the total protein content and the globulin content in the rat plasma are used as indexes for evaluating the medicine for treating the liver injury caused by the polygonum multiflorum. According to the scheme, the method for screening the medicine for treating the liver injury of the polygonum multiflorum is simple and easy to implement, the medicine for treating the liver injury of the polygonum multiflorum can be effectively screened by taking the white ball ratio, the total protein content and the globulin content in the blood plasma of an animal with the liver injury caused by the polygonum multiflorum as detection indexes, and a theoretical basis is also provided for clinical prevention and diagnosis of the liver injury of the polygonum multiflorum.